# US 2026/0060971 A1 · Methods of treating solid tumors having activation fgfr3 gene alterations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060971 A1
- Document ID: US20260060971A1
- Status: Published application
- Kind: A1
- Application number: 19/106,821
- Filed: 2023-08-30
- Published: 2026-03-05
- Earliest claimed: 2022-08-30
- Assignees: Tyra Biosciences, Inc.
- Applicants: Tyra Biosciences, Inc.
- Inventors: Hiroomi TADA; Robert L. HUDKINS; Piyush PATEL; Daniel C. BENSEN; Timothy Campbell BURN
- Web page: https://patentgrep.com/patent/US20260060971A1

## CPC

- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides methods of treating cancers that have activating FGFR3 gene alterations by administering a compound of Formula (I) as disclosed herein, or a pharmaceutically acceptable salt of a compound of Formula (I).

## Claims

### Claim 1

A method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I),
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer has an activating FGFR3 gene alteration.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cancer is urothelial cancer, breast cancer, endometrial cancer, lung cancer, ovarian cancer, or bladder cancer.

### Claim at position 4

-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is a locally advanced solid tumor.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is a metastatic solid tumor.

### Claim 13 (depends on 1)

The method of claim 1, wherein the activating FGFR3 gene alteration is a mutation.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mutation is or comprises one or more of
FGFR3 p.S84L;
FGFR3 p.G380R;
FGFR3 p.R621H;
FGFR3 p.R248C;
FGFR3 p.G380E;
FGFR3 p.K650E;
FGFR3 p.S249C;
FGFR3 p.A391V;
FGFR3 p.K650M;
FGFR3 p.P250R;
FGFR3 p.A391E;
FGFR3 p.K650T;
FGFR3 p.T264M;
FGFR3 p.M528I;
FGFR3 p.K650N;
FGFR3 p.G370C;
FGFR3 p.N540D;
FGFR3 p.R669Q;
FGFR3 p.S371C;
FGFR3 p.N540S;
FGFR3 p.G697C;
FGFR3 p.Y373C; or
FGFR3 p.N540K.

### Claim 15 (depends on 13)

The method of claim 13, wherein the mutation is or comprises one or more of
FGFR3 p.V553M;
FGFR3 p.V555M; or
FGFR3 p.V555L.

### Claim 16 (depends on 2)

The method of claim 2, wherein the activating FGFR3 gene alteration is a fusion.

### Claim 17 (depends on 16)

The method of claim 16, wherein the fusion is an FGFR3 rearrangements with an intact FGFR3 kinase domain and:
Breakpoint in intron 17 or exon 18 of FGFR3 and a known partner gene (e.g., TACC3, BAIAP2L1);
Breakpoint in intron 17 or exon 18 of FGFR3 and an in-frame novel partner gene; or
Breakpoint in intron 17 or exon 18 of FGFR3 and an intra-genic region or out-of-frame partner gene.

### Claim 18 (depends on 1)

The method of claim 1, wherein the patient is administered a compound of Formula (I).

### Claim 19 (depends on 1)

The method of claim 1, wherein the patient is administered a pharmaceutically acceptable salt of a compound of Formula (I).

### Claim 20 (depends on 19)

The method of claim 19, wherein the pharmaceutically acceptable salt of a compound of Formula (I) is the besylate salt.

### Claim 21 (depends on 1)

The method of claim 1, wherein the patient is administered the compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I) (on a Formula (I) basis), in an amount of 10 mg-120 mg per day of.

### Claim at position 16

-27. (canceled)

### Claim 28 (depends on 21)

The method of claim 21, wherein the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered orally.

### Claim 29 (depends on 1)

The method of claim 1, wherein the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered for at least 28 days.

### Claim 30 (depends on 29)

The method of claim 29, wherein the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I), is administered for 28 days.

### Claim 31 (depends on 1)

The method of claim 1, wherein the cancer exhibits a complete response (CR) or a partial response (PR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).

### Claim 32 (depends on 31)

The method of claim 31, wherein the cancer exhibits a complete response (CR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).

### Claim 33 (depends on 31)

The method of claim 31, wherein the cancer exhibits a partial response (PR), as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, to the administration of the compound of Formula (I), or pharmaceutically acceptable salt of a compound of Formula (I).

### Claim at position 23

-66. (canceled)
